10
total announcements
544644.BO · 15 min delayed
Corona Remedies Ltd
Corona Remedies Ltd has informed about its participation in an Analyst/Investor Conference on August 26, 2026, in Ahmedabad. The discussions will be based on publicly available information, and no unpublished price sensitive information will be shared.
Corona Remedies Ltd
Corona Remedies Ltd reported a 21.9% year-on-year revenue growth in Q1 FY27, surpassing its stated growth guidance of 15%. The company's India business delivered an impressive 22.7% year-on-year revenue growth, significantly outperforming the Indian Pharmaceutical Market (IPM) which grew by 11.6% during the same period.
Corona Remedies Ltd
Corona Remedies Ltd has announced that its officials will be attending investor conferences on August 13 and 14, 2026, in Mumbai, where they will discuss publicly available information and no unpublished price-sensitive information will be shared.
Corona Remedies Ltd
Corona Remedies Ltd has made available the audio recording of its Q1 FY27 earnings conference call with analysts and investors, which can be accessed on the company's website.
Corona Remedies Ltd
Corona Remedies Ltd has published unaudited financial results for the first quarter and three months ended June 30, 2026, which were approved by the Board of Directors on July 31, 2026. The results are available on the company's website and were published in the Financial Express newspaper.
Corona Remedies Ltd
CORONA Remedies Ltd has released an investor presentation for Q1 FY27, highlighting its operational and financial performance, including revenue growth, improved ranking in the IPM, and EU-GMP certification for its Oral Solid Dosage facility.
Corona Remedies Ltd
CORONA Remedies Ltd reported Q1FY27 unaudited financial results, with revenue growth of 21.9% and PAT growth of 30.1% YoY, driven by robust brand building and operational excellence.
Corona Remedies Ltd
Corona Remedies Ltd reported unaudited financial results for Q1FY27, with revenue growth of 21.9% and PAT growth of 30.1% Y-o-Y, driven by robust brand building and operational excellence.
Corona Remedies Ltd
Corona Remedies Ltd announced its unaudited financial results for Q1FY27, with a revenue growth of 21.9% and a PAT growth of 30.1% Y-o-Y, driven by robust brand building and operational excellence.
Corona Remedies Ltd
Corona Remedies Ltd will hold a conference call on August 3, 2026, to discuss its Q1 FY27 earnings.